Loading...

Eagle Pharmaceuticals, Inc.

EGRX•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$2.90
$0.60(26.09%)

Eagle Pharmaceuticals, Inc. (EGRX) Stock Overview

Explore Eagle Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 69.3/100

Key Financials

Market Cap38.1M
P/E Ratio1.07
EPS (TTM)$0.85
ROE0.17%

AI Price Forecasts

1 Week$2.00
1 Month$4.29
3 Months$0.00
1 Year Target$0.67

EGRX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Eagle Pharmaceuticals, Inc. (EGRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.67.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 1.07 and a market capitalization of 38.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for EGRXStats details for EGRX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for EGRXAnalyst Recommendations details for EGRX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

CEO

Michael Graves

Employees

134

Headquarters

50 Tice Boulevard, Woodcliff Lake, NJ

Founded

2014

Frequently Asked Questions

;